True increases in the global occurrence of thyroid cancer have been reported recently, owing to a steady rise in the incidence of papillary thyroid cancer (PTC), which accounts for approximately 85% of all thyroid cancers.1, 2, 3131I therapy is a conventional and effective treatment for unresectable disease, which is based on the nature of radioiodine avidity of tumour originating from thyroid follicular cells via the sodium/iodide symporter (NIS). The gene discussed is SLC5A5; the disease is neoplasm.